Profiling the physiological pitfalls of anti‐hepatitis C direct‐acting agents in budding yeast

Sofosbuvir and Daclatasvir are among the direct‐acting antiviral (DAA) medications prescribed for the treatment of chronic hepatitis C (CHC) virus infection as combination therapy with other antiviral medications. DAA‐based therapy achieves high cure rates, reaching up to 97% depending on the genoty...

Descripción completa

Detalles Bibliográficos
Autores principales: Yahya, Galal, Hashem Mohamed, Nashwa, Pijuan, Jordi, Seleem, Noura M., Mosbah, Rasha, Hess, Steffen, Abdelmoaty, Ahmed A., Almeer, Rafa, Abdel‐Daim, Mohamed M., Shulaywih Alshaman, Hamoud, Juraiby, Ibrahim, Metwally, Kamel, Storchova, Zuzana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449668/
https://www.ncbi.nlm.nih.gov/pubmed/34378349
http://dx.doi.org/10.1111/1751-7915.13904

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449668/
https://www.ncbi.nlm.nih.gov/pubmed/34378349
http://dx.doi.org/10.1111/1751-7915.13904

Ejemplares similares